Selexis SA, a JSR Life Sciences company, has signed a service agreement with Pandion Therapeutics, Inc. to advance the development of Pandion’s PT627, a systemically-acting PD-1 agonist antibody for the potential treatment of autoimmune and inflammatory diseases. Pandion will leverage Selexis’ proprietary SUREtechnology Platform to rapidly develop the research cell banks (RCBs) necessary to advance PT627 to human trials.   Selexis’ modular SUREtechnology Platform facilitates the rapid, stable,...